Use of NPSP558 in the Treatment of Hypoparathyroidism
Status:
Completed
Trial end date:
2011-09-28
Target enrollment:
Participant gender:
Summary
Use of PTH (1-84) a recombinant hormone in escalating doses for the treatment of adults with
hypoparathyroidism. The use of PTH should result in a decrease of calcium and vitamin D
supplements.